Abstract: The present disclosure provides a method for preparing a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors, the composition prepared by the method, and use of the composition for treating arthritis. The composition of the present disclosure achieves the effect of treating arthritis through various efficacy experiments.

Abstract: The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.

Abstract: The present invention relates to a method for preparing a modified stem cell, including the following steps: a cell culture step: culturing stem cells in a first culture medium of a culture dish at a predetermined cell density, and removing the first culture medium after a first culture time to obtain a first cell intermediate; an activity stimulation step: preserving the first cell intermediate in a freezing container having a cell cryopreservation solution, and performing a constant temperature stimulation treatment or a variable temperature stimulation treatment for at least more than 1 day; and a product collection step: after completing the activity stimulation step, placing the freezing container in an environment at a thawing temperature for thawing, and then removing the cell cryopreservation solution to obtain the modified stem cell. The modified stem cell can release at least one or more of IL-4, IL-5, IL-13, G-CSF, Fractalkine, and EGF.

Abstract: A stacked package structure and a manufacturing method thereof are provided. The stacked package structure includes an upper redistribution layer, a first chip, and an upper molding layer. The first chip is disposed on the upper redistribution layer and is electrically connected to the upper redistribution layer. The upper molding layer is disposed on the first chip and the upper redistribution layer, and is configured to package the first chip. The upper molding layer includes a recess, the recess is recessed relative to a surface of the upper molding layer away from the upper redistribution layer, and the recess is circumferentially formed around a periphery of the upper molding layer.

Abstract: A button mechanism includes a button, a module, and a thin sheet spring. The thin sheet spring is in physical communication with the button and with the module. The thin sheet spring exerts a tension force on the button and the module to bias the button toward a normal position. In response to a force greater than the tension force being exerted on the button, a portion of the thin sheet stretches to enable the button to be placed in a contact position. In response to the force being removed from the button, the tension force causes the thin sheet to snap back to an original position and biases the button toward the normal position.

Abstract: Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved.

Abstract: The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.

Abstract: The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising TS stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the TS stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1?, IL-1?, IL-4, IL-5, IL-13, IFN?, TGF? and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

Abstract: The present disclosure provides a method for treating arthritis by using a stem cell preparation. The stem cell preparation of the present disclosure can effectively delay cartilage degeneration caused by arthritis, and it is confirmed by whole blood analysis and blood biochemical analysis that the stem cell preparation in the form of three-dimensional stem cell spheres provides a safe treatment for arthritis. The present disclosure also provides a method for preparing the stem cell preparation.

Abstract: A method for stably amplifying a pluripotent stem cell comprises the following steps: (a) a cell implantation step: implanting pluripotent stem cells directly into a porous scaffold such that the porous scaffold contains 1×104 or more of the pluripotent stem cells; and (b) a cell amplification step: immersing the porous scaffold in a specific culture medium which is xeno-free (XF) and performing amplification culture at an ambient temperature of 35.5-39.5° C. and a CO2 concentration of 5% to obtain the amplified pluripotent stem cells, wherein the amplified pluripotent stem cells aggregate to present an embryoid body state. The amplification method of the present disclosure can easily obtain an excellent effect of increasing an amplification multiple of the pluripotent stem cells to about 3 times or more.

Abstract: Uses of n-butylidenephthalide (BP) in dopaminergic progenitor cell transplantation are provided, wherein the uses include using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation, and using a combination of BP and BP-treated dopaminergic progenitor cells in dopaminergic progenitor cell transplantation. The uses especially relate to using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation on Parkinson’s disease.

Abstract: A high-temperature flow-splitting component, applicable to a temperature range from a first temperature to a second temperature, includes an entrance channel, at least one primary channel and at least one subordinate channel. The entrance channel is used for introducing a fluid at a total flow rate. The at least one primary channel for introducing the fluid from the entrance channel at a first flow rate is connected with the entrance channel by a first angle ranging from 90°˜270°. The at least one subordinate channel for introducing the fluid from the entrance channel at a second flow rate is connected with the at least one primary channel by a second angle ranging from 30°˜150°. A sum of the first flow rate and the second flow rate is equal to the total flow rate.

Abstract: This invention provides a light-concentrating structure with photosensitivity enhancing effect, including the substrate, buried layer, first electrode layer, second electrode layer, dielectric layer and interconnection structure. The substrate is equipped with a housing space; the buried layer is arranged above the substrate with the housing space; the first electrode layer is arranged above the buried layer; the second electrode layer is arranged in the middle of the first electrode layer; the dielectric layer is arranged above the second electrode layer; the interconnection structure is arranged above the substrate and the first electrode layer surrounding the dielectric layer, which forms an opening and a light-concentrating recess groove.

Abstract: This invention provides a light-concentrating structure with photosensitivity enhancing effect, including the substrate, buried layer, first electrode layer, second electrode layer, dielectric layer and interconnection structure. The substrate is equipped with a housing space; the buried layer is arranged above the substrate with the housing space; the first electrode layer is arranged above the buried layer; the second electrode layer is arranged in the middle of the first electrode layer; the dielectric layer is arranged above the second electrode layer; the interconnection structure is arranged above the substrate and the first electrode layer surrounding the dielectric layer, which forms an opening and a light-concentrating recess groove.

Abstract: Achieving homogeneous and heterogeneous integration for 2.5D and 3D integrated circuit, chip-to-wafer, chip-to-substrate, or wafer-to-wafer bonding is an essential technology. The landing wafer or substrate is bonded with a carrier by using a temporary bonding material before thinning the landing wafer to the desired thickness. Upon completion of redistribution layer formation, Cu pad formation, or other backside processing, dies or wafers with through-silicon vias are stacked onto the landing substrate before molding and singulation. As the landing wafer usually has interconnection metals in the bond line, and those interconnection metals are typically made from lead-free solder alloys, deformation of those solder alloys during thermocompression bonding becomes an issue for manufacturers. To address this issue, a polymeric material with desired strengths is coated on the device wafer to form a conformal protective layer on top of solder alloys, thus enabling temporary bonding and debonding processes.

Abstract: Methods are disclosed to prepare permanent materials that can be coated onto microelectronic substrates or used for other structural or optical applications. The permanent materials are thermally stable to at least 300° C., cure using a photo or thermal process, exhibit good chemical resistance (including during metal passivation), and have a lifespan of at least 5 years, preferably at least 10 years, in the final device. Advantageously, these materials can also be bonded at room temperature. The materials exhibit no movement or squeeze-out after bonding and adhere to a variety of substrate types. A chip-to-chip, chip-to-wafer, and/or wafer-to-wafer bonding method utilizing this material is also described.

Abstract: A controlling device of a fuel cell system with multiple stack towers and a controlling method thereof are provided. The controlling device comprises a temperature sensing equipment, a processor and a pulse width modulation circuit. The fuel cell system comprises multiple fuel cell stacks. The controlling method further comprises: calculating an average temperature of the fuel cell stacks based on the temperatures of the fuel cell stacks by the temperature sensing equipment; determining whether differences between the average temperature and the temperatures of the fuel cell stacks fall within a preset range of average temperature difference by the processor, and adjusting an output current of at least one of the fuel cell stacks by the pulse width modulation circuit commanded by the processor when the difference between the average temperature and the temperature of the at least one fuel cell stack falls outside the preset range of average temperature difference.

Abstract: A high-temperature flow-splitting component, applicable to a temperature range from a first temperature to a second temperature, includes an entrance channel, at least one primary channel and at least one subordinate channel. The entrance channel is used for introducing a fluid at a total flow rate. The at least one primary channel for introducing the fluid from the entrance channel at a first flow rate is connected with the entrance channel by a first angle ranging from 90°˜270°. The at least one subordinate channel for introducing the fluid from the entrance channel at a second flow rate is connected with the at least one primary channel by a second angle ranging from 30°˜150°. A sum of the first flow rate and the second flow rate is equal to the total flow rate.

Abstract: The present invention relates to a pharmaceutical composition for treating cardiac hypertrophy, comprising at least a stem cell and a pharmaceutically acceptable vehicle, wherein the stem cell is prepared by a pretreatment reaction of reacting with an n-butylidenephthalide (BP). The pharmaceutical composition of the present invention can be administered into a body of a hypertensive patient by remote intramuscular injection, so as to reduce superoxide content in the myocardium, increase STAT3 activity, and increase the content of M2 macrophages that promote inflammation resolution, and further effectively treat the symptoms of cardiac hypertrophy caused by hypertension.

Abstract: The present invention provides a new method for decreasing level of a proinflammatory cytokine in a subject, which is further able to treating cytokine release syndrome caused by CAR T-cell therapy or a disorder mediated by an overproduction of a proinflammatory cytokine. The method comprises administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition which is comprising at least one selected from the group consisting of Phenothiazine derivatives, Graptopetalum paraguayense extract, Rhodiola rosea extract and Histone Deacetylase (HDAC) inhibitors.